Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

@inproceedings{Shitara2016RandomizedSO,
  title={Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G},
  author={Kohei Shitara and Kimio Yonesaka and Tadamichi Denda and Kentaro Yamazaki and Toshikazu Moriwaki and Masahiro Tsuda and Toshimi Takano and Hiroyuki Okuda and Tomohiro Nishina and Kazuko Sakai and Kazuto Nishio and Shoji Tokunaga and Takeharu Yamanaka and Narikazu Boku and Ichinosuke Hyodo and Kei Muro},
  booktitle={Cancer science},
  year={2016}
}
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA) and serum proteins as predictive biomarkers. Patients with WT KRAS exon 2 mCRC refractory to first-line chemotherapy containing oxaliplatin and bevacizumab were randomly assigned to panitumumab… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Frequencies of KRAS, NRAS, and BRAF mutations in circulating tumor DNA

  • S Table
  • The Authors. Cancer Science published by John…
  • 2016

FIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer

  • S Misale, R Yaeger, S Hobor
  • Clin Colorectal Cancer
  • 2015

Combined epiregulin ( EREG ) and amphiregulin ( AREG ) expression levels as a biomarker of prognosis and panitumumab benefit in RAS - wt advanced colorectal cancer ( aCRC )

  • JF Seligmann, F Elliott, S Richman
  • J Clin Oncol
  • 2014

Similar Papers

Loading similar papers…